Trials & Filings

Advaxis Improves 18-Month Survival in Cervical Cancer

Ph II trial shows 28% survival

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Advaxis has posted final 18-month survival data from its randomized Phase II study evaluating the safety and efficacy of ADXS-HPV with and without cisplatin in 110 patients with recurrent cervical cancer. The primary endpoint of the study is overall survival. Data will be presented at the 2013 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The final 18-month survival data are 28% (31/110), which is updated from the preliminary 18-month survival of 22% (16/73) reported  in June 2013....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters